Docoh
Loading...

CPMV Mosaic ImmunoEngineering

Press releases

Pro users get this 30m faster
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates
12 Oct 21
Biotech, News, Press Releases
Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cellsVaccine candidates hold potential for rapid response to regions that may lack
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
6 Oct 21
Biotech, News, Press Releases
- Nanoparticle-based technology complements the company's intratumoral technology platform -NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"),
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
1 Oct 21
Biotech, Events, Press Releases
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
27 Sep 21
Biotech, News, Press Releases
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots -- Delivery system is transportation and storage friendly with no refrigeration
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
23 Sep 21
Biotech, News, Press Releases
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studiesEpitopes used in the vaccine candidates are located in regions that are not known to be
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
21 Sep 21
Biotech, News, Press Releases
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications -- Data Supporting the Potential of Lead Vaccine Candidates was Funded Through